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to view.Drug Delivering Technology for Endovascular Management of Infrainguinal Peripheral
Artery Disease827Karan Sarode, David A. Spelber, Deepak L. Bhatt, Atif Mohammad, Anand Prasad,
Emmanouil S. Brilakis, Subhash BanerjeeEndovascular management of peripheral artery disease has historically had high restenosis rates
leading to repeat interventions. The innovation of locally administered, antiproliferative drug
delivering technology is an attempt to overcome these shortcomings. This review highlights the
results of numerous completed and ongoing clinical trials examining the efﬁcacy and indications of
use of these novel devices. Additionally, it explores combination therapies and promising new
treatment modalities for the management of peripheral artery disease, along with the challenges
and safety concerns that may have contributed to the potential delay in the U.S. Food and Drug
Administration approval of these devices.CLINICAL RESEARCH
CORONARY Three-Year Outcomes After Revascularization With Everolimus- and
Sirolimus-Eluting Stents From the SORT OUT IV Trial840Lisette Okkels Jensen, Per Thayssen, Michael Maeng, Evald Høj Christiansen,
Jan Ravkilde, Knud Nørregaard Hansen, Anne Kaltoft, Hans Henrik Tilsted,
Morten Madsen, Jens Flensted Lassen, for the Scandinavian Organization for
Randomized Trials With Clinical Outcome SORT OUT IV InvestigatorsIn the SORT OUT IV TRIAL (SORT OUT), the outcomes at 3 years were assessed with focus on very late
deﬁnite stent thrombosis. The composite primary endpoint occurred in 9.8% of the everolimus-
eluting stent (EES) group and in 11.1% of the sirolimus-eluting stent group (hazard ratio [HR]:
0.89, 95% conﬁdence interval [CI]: 0.70 to 1.12). The rate of deﬁnite stent thrombosis was lower
in the EES group (0.2% vs. 1.4%, HR: 0.15, 95% CI: 0.04 to 0.50), which was largely attributable
to a lower risk of very late deﬁnite stent thrombosis: 0.1% versus 0.8% (HR: 0.09, 95% CI: 0.01
to 0.70).CONTINUED ON PAGE A-27
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AUGUST 2014 VOLUME 7, NUMBER 8Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
in Patients With ST Elevation Myocardial Infarction: RACES-MI Trial849Emilio Di Lorenzo, Rosario Sauro, Attilio Varricchio, Michele Capasso, Tonino Lanzillo,
Fiore Manganelli, Giannignazio Carbone, Francesca Lanni, Maria Rosaria Pagliuca,
Giovanni Stanco, Giuseppe Rosato, Harry Suryapranata, Giuseppe De LucaNo data have been reported so far on the long-term beneﬁts and safety of the new generation
drug-eluting stent(s) in ST-segment elevation myocardial infarction (STEMI). Therefore, the
authors compared everolimus-eluting stent(s) (EES) with sirolimus-eluting stent(s) (SES) in 500
STEMI patients undergoing primary angioplasty. At 3-year follow-up, no signiﬁcant difference was
observed between EES and SES in major adverse cardiac events (p ¼ 0.17), Cardiac death (p ¼
0.53), recurrent MI (p ¼ 0.13) and target vessel revascularization (p ¼ 0.99). However, EES was
associated with a signiﬁcant reduction in stent thrombosis (p ¼ 0.035). This study shows that
among STEMI patients, EES, as compared to SES, is associated with a signiﬁcant reduction in stent
thrombosis.
A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in
Women Undergoing Percutaneous Coronary Intervention: The SAFE-PCI for Women
(Study of Access Site for Enhancement of PCI for Women) Trial857Sunil V. Rao, Connie N. Hess, Britt Barham, Laura H. Aberle, Kevin J. Anstrom,
Tejan B. Patel, Jesse P. Jorgensen, Ernest L. Mazzaferri Jr., Sanjit S. Jolly, Alice Jacobs,
L. Kristin Newby, C. Michael Gibson, David F. Kong, Roxana Mehran, Ron Waksman,
Ian C. Gilchrist, Brian J. McCourt, John C. Messenger, Eric D. Peterson,
Robert A. Harrington, Mitchell W. KrucoffWomen are at increased risk of bleeding and vascular complications after percutaneous coronary
intervention (PCI). Rao and colleagues conducted a registry-based randomized trial to determine
the efﬁcacy and feasibility of radial access in women. The trial was stopped early for a lower than
expected event rate. There was no signiﬁcant difference in the primary efﬁcacy endpoint between
radial and femoral access in women undergoing PCI, but in women undergoing cardiac
catheterization or PCI, radial access signiﬁcantly reduced bleeding and vascular complications.
Access site crossover was signiﬁcantly higher in women assigned to radial access, but more
women preferred radial access.
SEE ADDITIONAL CONTENT ONLINEIntravascular Ultrasound-Derived Minimal Lumen Area Criteria for Functionally
Signiﬁcant Left Main Coronary Artery Stenosis868Seung-Jung Park, Jung-Min Ahn, Soo-Jin Kang, Sung-Han Yoon, Bon-Kwon Koo,
Jong-Young Lee, Won-Jang Kim, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim,
Cheol Whan Lee, Seong-Wook ParkEvaluation of signiﬁcant left main coronary artery (LMCA) stenosis remains challenging. Therefore,
the authors examined the usefulness of the intravascular ultrasound (IVUS) minimal lumen area
(MLA) for the functional signiﬁcance of LMCA stenosis using fractional ﬂow reserve as the
standard. They found that IVUS MLA was an independent factor of functionally signiﬁcant stenosis
with an optimal cutoff value of 4.5 mm2. In conclusion, in patients with isolated ostial and shaft
intermediate LMCA stenosis, an IVUS-derived MLA of #4.5 mm2 is a useful index of a fractional
ﬂow reserve of #0.80.CONTINUED ON PAGE A-28
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AUGUST 2014 VOLUME 7, NUMBER 8STRUCTURAL Survival of Transcatheter Mitral Valve Repair Compared With Surgical
and Conservative Treatment in High-Surgical-Risk Patients875Martin J. Swaans, Annelies L. M. Bakker, Arash Alipour, Martijn C. Post,
Johannes C. Kelder, Thom L. de Kroon, Frank D. Eefting, Benno J. W. M. Rensing,
Jan A. S. Van der HeydenUp to 50% of patients with symptomatic severe mitral valve (MV) regurgitation (MR) are denied for
surgery due to high perioperative risk. Transcatheter MV repair might be an alternative. Swaans and
colleagues compared survival between transcatheter MV repair using the MitraClip system (Abbott
Vascular, Santa Clara, California) (n ¼ 139), MV surgery (n ¼ 53), and conservative treatment
(n ¼ 59) in high-surgical-risk patients with symptomatic severe MR. The authors show that despite
a higher logistic European System for Cardiac Operative Risk Evaluation, high-surgical-risk patients
with severe symptomatic MR treated with transcatheter MV repair show similar survival rates
compared with surgically treated patients, with both displaying survival beneﬁt compared with
conservative treatment.n EDITORIAL COMMENT
The Saga Continues: Does Mitral Valve Repair Improve Survival in
Secondary Mitral Regurgitation?882Robert O. Bonow
Quantity and Location of Aortic Valve Complex Calciﬁcation Predicts Severity
and Location of Paravalvular Regurgitation and Frequency of Post-Dilation
After Balloon-Expandable Transcatheter Aortic Valve Replacement885Omar K. Khalique, Rebecca T. Hahn, Hemal Gada, Tamim M. Nazif, Torsten P. Vahl,
Isaac George, Bindu Kalesan, Molly Forster, Mathew B. Williams, Martin B. Leon,
Andrew J. Einstein, Todd C. Pulerwitz, Gregory D. N. Pearson, Susheel K. KodaliParavalvular regurgitation (PVR) and the need for balloon post-dilation (PD) are important outcomes
following transcatheter aortic valve replacement given the associated morbidity and mortality that
may occur. Previous literature has been mixed regarding the role of calciﬁcation in different
locations of the aortic valve complex on PVR and PD. In the current study, Khalique et al. have
found that calciﬁcation in all regions of the aortic valve complex signiﬁcantly predicts PVR and PD.
Leaﬂet and anchoring zone calciﬁcation are independent predictors of PVR and PD when factoring
in relative valve to annulus sizing.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Paravalvular Regurgitation and Post-Deployment Balloon Dilation
After Transcatheter Aortic Valve Replacement: Can We Predict and Prevent?895Paolo RaggiCONTINUED ON PAGE A-29
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AUGUST 2014 VOLUME 7, NUMBER 8Comparison of Transfemoral Transcatheter Aortic Valve Replacement Performed 898
in the Catheterization Laboratory (Minimalist Approach) Versus Hybrid Operating
Room (Standard Approach): Outcomes and Cost Analysis
Vasilis Babaliaros, Chandan Devireddy, Stamatios Lerakis, Robert Leonardi,
Sebastian A. Iturra, Kreton Mavromatis, Bradley G. Leshnower, Robert A. Guyton,
Mihir Kanitkar, Patricia Keegan, Amy Simone, James P. Stewart, Nima Ghasemzadeh,
Peter Block, Vinod H. ThouraniAs experience with transcatheter aortic valve replacement (TAVR) has increased, some centers have
performed transfemoral TAVR in a standard cardiac catheterization laboratory without general
anesthesia or transesophageal echocardiography. Babaliaros and colleagues compared the safety,
efﬁcacy, and cost of such a minimalist approach to the current standard approach performed in a
hybrid operating room. The minimalist approach was associated with equivalent safety and
efﬁcacy outcomes compared with the standard approach, with lower costs and shorter length of
stay. The authors believe that these results have important implications for the ﬁnancial viability
of U.S. TAVR programs in the future.
Results of the U.S. Food and Drug Administration Continued Access Clinical Trial
of the GORE HELEX Septal Occluder for Secundum Atrial Septal Defect905Alexander J. Javois, Jonathan J. Rome, Thomas K. Jones, Evan M. Zahn,
Craig E. Fleishman, Ricardo H. Pignatelli, Larry A. Latson,
for the Gore HELEX Continued Access Study GroupThe immediate, 1-, and 5-year follow-up outcomes of the Continued Access clinical trial of the GORE
HELEX Septal Occluder (W. L. Gore & Associates, Inc., Flagstaff, Arizona) are reported. The overall
clinical success was 96.7%, and major adverse event rate was 3.6%. Wire frame fractures were
seen in 11.7% of patients with no clinical symptoms. A trivial, clinically insigniﬁcant leak was seen,
or could not be ruled out, in 26.6% of patients at the 5-year evaluation, but no clinically
signiﬁcant leaks were seen. No patient experienced an erosion or sudden catastrophic event.CONTINUED ON PAGE A-30
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AUGUST 2014 VOLUME 7, NUMBER 8PERIPHERAL VASCULAR Predictors of Recurrent Events in Patients With Cryptogenic Stroke and Patent Foramen
Ovale Within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in
Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical
Embolism Through a Patent Foramen Ovale) Trial913Sammy Elmariah, Anthony J. Furlan, Mark Reisman, David Burke, Moshe Vardi,
Neil J. Wimmer, Shuqiong Ling, Xiaohua Chen, David M. Kent, Joseph Massaro,
Laura Mauri, for the CLOSURE I InvestigatorsThis is a post-hoc analysis aimed at identifying risk factors for the development of recurrent
neurologic events in patients with cryptogenic stroke and patent foramen ovale within the
CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or
Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen
Ovale) trial. In 909 patients, the incidence of recurrent events was 5.7% at 2 years. Diabetes,
index transient ischemic attack, and the detection of atrial ﬁbrillation after enrollment
independently predicted recurrent neurologic events. Recurrent neurologic events were also more
frequent in subjects with a lower RoPE (Risk of Paradoxical Embolism Score). These ﬁndings
suggest an alternative etiology to paradoxical embolism was frequently responsible for recurrent
events within the CLOSURE I trial.n EDITORIAL COMMENT
The Paradox of Paradoxical Embolism and Recurrent Stroke 921
Alex Abou-Chebl
Lower Extremity Revascularization Using Directional Atherectomy: 12-Month
Prospective Results of the DEFINITIVE LE Study923James F. McKinsey, Thomas Zeller, Krishna J. Rocha-Singh, Michael R. Jaff,
Lawrence A. Garcia, on behalf of the DEFINITIVE LE InvestigatorsThe goal of this study was to objectively assess the safety and effectiveness of directional
atherectomy (DA) in patients with claudication or critical limb ischemia (CLI). Primary endpoints
were 12-month primary patency for claudicants and freedom from major unplanned amputation for
CLI subjects. CLI secondary endpoints included 12-month primary patency. In 800 subjects, the 12-
month primary patency rate was 78% in claudicants including 77% in the diabetic subgroup versus
78% in the nondiabetic subgroup (p < 0.001). The rate of freedom from major unplanned
amputation at 12 months in CLI subjects was 95% with a 71% primary patency rate. DA is safe and
effective treatment at 12 month for a diverse patient population.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
The DEFINITIVE LE: Atherectomy’s Ability to Leave No Trace or Need for More
DEFINITIVE Data?934Andrew J.P. KleinCONTINUED ON PAGE A-31
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INTERVENTIONDifferent Findings in a Calciﬁed Nodule Between Histology and Intravascular Imaging
Such as Intravascular Ultrasound, Optical Coherence Tomography,
and Coronary Angioscopy937Hiroyuki Hao, Kenichi Fujii, Masahiko Shibuya, Takahiro Imanaka, Rika Kawakami,
Kinta Hatakeyama, Yujiro Asada, Tohru Masuyama, Seiichi Hirota
360 Degrees Out of Trouble: A Novel Wiring Technique Required in
Management of Acute Occlusion of a Giant Coronary Aneurysm939Don Myears, Sirish Parvathaneni
n ONLINE FEATURE A Novel Quick and Easy Test for Radial Artery Occlusion
With the Laser Doppler Scane89Salvatore De Rosa, Francesco Passafaro, Alberto Polimeni, Sabato Sorrentino, Ciro Indolﬁ
n ONLINE FEATURE Endovascular Stenting of Suture Line Supravalvular Pulmonic
Stenosis After Orthotopic Heart Transplantation Using Rapid Pacing Stabilizatione91Justin Z. Lee, Kwan S. Lee, Aiden Abidov, Ricardo A. Samson, Kapildeo Lotun
n ONLINE FEATURE Non–ST-Segment Elevation Myocardial Infarction Related to
Vulnerable Neoatheroma in Bare-Metal Stents 2 Years After Percutaneous
Coronary Intervention of a Coronary Saphenous Vein Grafte95Tomasz Roleder, Wojciech Wanha, Grzegorz Smolka, Andrzej Ochała,
Wojciech Wojakowski
n ONLINE FEATURE Seeing Through the Haze: Optical Coherence Tomography
Demonstrates the Unanticipated Cause of a Left Anterior Descending
Coronary Artery Lesione97Suneil Kumar Aggarwal, Alexander Sirker, Howard Swanton, Muhiddin Ozkor
n ONLINE FEATURE Successful Balloon Mitral Valvotomy in a Case of Inferior
Vena Cava Obstruction: Where There Is a Will, There Is a Waye99Madan Tarun, Garg Rajiv, Thakkar Bhavesh
n ONLINE FEATURE A Case of True Left Main Bifurcation Treated With Bioresorbable
Everolimus-Eluting Stent V-Stentinge103Katsumasa Sato, Azeem Latib, Vasileios F. Panoulas, Toru Naganuma, Tadashi Miyazaki,
Antonio Colombo
n ONLINE FEATURE Tardive Coronary Obstruction By a Native Leaﬂet After
Transcatheter Aortic Valve Replacement in a Patient With Heavily Calciﬁed
Aortic Valve Stenosise105Gennaro Giustino, Matteo Montorfano, Alaide Chieffo, Vasileios Panoulas,
Pietro Spagnolo, Azeem Latib, Remo Daniel Covello, Ottavio Alﬁeri, Antonio Colombo
n ONLINE FEATURE Modiﬁed T-Technique With Bioresorbable Scaffolds Ensures
Complete Carina Coverage: An Optical Coherence Tomography Studye109Nicolas Van Mieghem, Jeroen J. Wilschut, Jurgen Ligthart, Karen Witberg,
Robert-Jan M. van Geuns, Evelyn Regar
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n REPLY
Akhil Parashar, Shikhar Agarwal, Navkaranbir S. Bajaj, E. Murat Tuzcu, Samir R. KapadiaEDITOR’S PAGE A Day at the Beach 944
Spencer B. King IIICORRECTIONS 946
